Best Rectal Cancer Doctors in Hyderabad — CION's Dedicated Rectal Cancer Panel

The best doctor depends on your tumour location and stage. For surgery, look for an onco-trained surgeon with documented experience in Total Mesorectal Excision (TME) and sphincter-preserving techniques — not a general surgeon. For chemotherapy and neoadjuvant therapy, look for a medical oncologist with GI experience. For radiation, central to rectal cancer, look for a radiation oncologist current with short-course and long-course neoadjuvant protocols. At CION, every rectal cancer case is reviewed by a multidisciplinary tumour board, with surgery led by Dr. Sridhar Kamani (DrNB Surgical Gastroenterology).

Not necessarily, and this is the single most important question to ask before any rectal cancer surgery. Whether you need a permanent colostomy depends mainly on tumour location: cancers in the upper and middle rectum almost always allow sphincter-preserving surgery (Low Anterior Resection, LAR); cancers very close to the anus may require intersphincteric resection (ISR) — a modern sphincter-preserving option many centres do not offer; only the lowest tumours involving the sphincter itself require abdominoperineal resection (APR) with a permanent colostomy. Many patients with sphincter-preserving surgery have a temporary loop ileostomy for 8–12 weeks to allow healing, which is then reversed.

Total Mesorectal Excision (TME) is the gold-standard surgical technique for rectal cancer — removing the rectum together with the entire mesorectum (the fatty tissue containing lymph nodes and blood vessels) along precise anatomical planes. Compared to less precise resection, TME significantly reduces local recurrence and improves long-term survival. TME requires specific onco-surgical training; general surgeons performing rectal surgery without TME training have meaningfully worse outcomes. At CION, every rectal cancer surgery uses the TME technique.

For most Stage II and Stage III rectal cancers, yes — neoadjuvant (pre-operative) chemoradiation or Total Neoadjuvant Therapy (TNT) is the current standard. The benefits are significant: shrinking the tumour increases the chance of sphincter-preserving surgery, sterilising microscopic lymph node disease, and reducing local recurrence. For Stage I rectal cancer, surgery alone is often appropriate. The decision is made by the tumour board based on MRI staging and biopsy findings.

Possibly — and this is one of the most important developments in rectal cancer in the past decade. Approximately 20–30% of patients who receive Total Neoadjuvant Therapy (full chemotherapy plus chemoradiation before surgery) achieve a complete clinical response — meaning no detectable tumour remains. For these patients, careful watch-and-wait surveillance is an accepted alternative to surgery, with comparable long-term outcomes for selected cases. Watch-and-wait requires close monitoring with regular MRI, endoscopy, and clinical examination. CION offers watch-and-wait as a real option for complete responders, in line with current international protocols — many centres in Hyderabad do not.

Once rectal cancer is confirmed on biopsy, treatment must be led by oncology — not a general surgeon. Rectal cancer surgery is technically demanding because the rectum sits deep in the pelvis, close to nerves controlling bowel, bladder, and sexual function. TME technique and sphincter-preserving decisions require onco-specific training. Neoadjuvant therapy decisions require medical and radiation oncology. A general surgeon performing the surgery alone is not the right pathway.

Some bowel function changes after sphincter-preserving rectal surgery are common — typically more frequent bowel movements, urgency, or fragmentation of stools (called Low Anterior Resection syndrome or LARS). Most patients improve significantly over 12–18 months. Sexual and urinary function depend on how well the autonomic pelvic nerves are preserved during surgery — TME with nerve-sparing technique is critical. Centres without onco-surgical training have higher rates of nerve injury and resulting function loss. Ask any centre directly about their approach to nerve preservation.

Rectal cancer is cancer of the last 15 cm of the large intestine — the part inside the pelvis. Colon cancer is cancer of the upper large intestine — outside the pelvis. Although they are both 'colorectal cancers' and share many risk factors and biology, the treatment is fundamentally different: rectal cancer often requires pre-operative chemoradiation and uses TME surgical technique; colon cancer typically goes straight to surgery followed by adjuvant chemotherapy where indicated. Sphincter preservation and stoma decisions are specific to rectal cancer.

A second opinion is especially valuable before rectal cancer surgery — both because the question of sphincter preservation varies meaningfully across surgeons, and because some centres skip neoadjuvant therapy that could improve sphincter preservation or even enable watch-and-wait. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your MRI, biopsy, and existing recommendation and provides a documented opinion you can take anywhere.

Costs vary by stage and treatment. Low anterior resection or APR ranges approximately ₹3,00,000 to ₹6,00,000; neoadjuvant chemoradiation adds ₹2,00,000 to ₹4,00,000 over 5–6 weeks; adjuvant chemotherapy after surgery adds further; immunotherapy for MSI-high advanced disease is significantly higher per cycle. For a detailed cost breakdown by treatment type, see our rectal cancer treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate before treatment begins. Aarogyasri, EMI, and cashless insurance are accepted.